Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 1:23 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1825–1848 of 13,612 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Dermatoses Clear all

Conditions: Breast Cancer
Interventions: therapeutic conventional surgery, whole breast irradiation; Procedure · Radiation
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 40 Years and older · Female only
Enrollment: 270 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2023
U.S. locations: 350
States / cities: Hot Springs, Arkansas • Dublin, California • Emeryville, California + 216 more

Conditions: Post Inflammatory Hyperpigmentation
Interventions: Pigment Balancing Peel, Discoloration Defense Serum, LHA Cleansing Gel, Hydrating B5 Gel, Daily Brightening Sunscreen; Other
Lead sponsor: Narrows Institute for Biomedical Research; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 1
States / cities: Brooklyn, New York

Conditions: Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Triple-Negative Breast Carcinoma
Interventions: Biospecimen Collection, Cognitive Assessment, Dietary Intervention, Medical Device Usage and Evaluation, Questionnaire Administration; Procedure · Other
Lead sponsor: Ohio State University Comprehensive Cancer Center; Other
Eligibility: 40 Years to 65 Years · Female only
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 2
States / cities: New Haven, Connecticut • Columbus, Ohio

Conditions: Acne
Interventions: Tretinoin or Adapalene, Isotretinoin; Drug
Lead sponsor: University of California, Davis; Other
Eligibility: 12 Years to 30 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2015
U.S. locations: 2
States / cities: Davis, California • Sacramento, California

Conditions: Milk and/or Peanut Allergy
Interventions: Peanut powder and Oat flour, Peanut flour and Oat flour (placebo for peanut flour), Dry Milk Powder and Corn Starch (placebo for Milk powder), Baked milk and Rice milk (placebo for Baked milk); Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 3 Years to 21 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Sarcoma, Kaposi, HIV Infections
Interventions: Tin ethyl etiopurpurin; Drug
Lead sponsor: Clinical Solutions; Industry
Eligibility: 18 Years and older
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 6
States / cities: Los Angeles, California • San Francisco, California • Denver, Colorado + 2 more

Conditions: Skin and Subcutaneous Tissue Bacterial Infections, Wound Infection, Cutaneous Abscess, Burn Infection, Cellulitis
Interventions: AFN-12520000; Drug
Lead sponsor: Affinium Pharmaceuticals, Ltd; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 103 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012
U.S. locations: 12
States / cities: Buena Park, California • Chula Vista, California • La Mesa, California + 9 more

Conditions: Breast Cancer, Breast Diseases
Interventions: Evaluation of BIT-Motion software; Diagnostic Test
Lead sponsor: Endeavor Health; Other
Eligibility: 18 Years and older · Female only
Enrollment: 68 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Evanston, Illinois

Conditions: Breast Neoplasms, Breast Cancer, Breast Carcinoma, Malignant Neoplasm of Breast, Cancer of Breast, Mammary Neoplasm, Human, Human Mammary Carcinoma, Malignant Tumor of Breast, Mammary Cancer, Mammary Carcinoma, Anxiety, Fear, Neoplasm Remission, Spontaneous, Spontaneous Neoplasm Regression, Regression, Spontaneous Neoplasm, Remission, Spontaneous Neoplasm, Spontaneous Neoplasm Remission
Interventions: Acceptance and Commitment Therapy, Survivorship Education, Enhanced Usual Care; Behavioral
Lead sponsor: Indiana University; Other
Eligibility: 18 Years to 99 Years · Female only
Enrollment: 91 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Breast Cancer, Ovarian Neoplasm, Pain
Interventions: Omega-3 fatty acid, Placebo, Paclitaxel; Dietary Supplement · Drug
Lead sponsor: New Mexico Cancer Research Alliance; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 2
States / cities: Albuquerque, New Mexico

Conditions: Breast Cancer
Interventions: Curcumin C3 Complex, Placebo; Drug
Lead sponsor: University of Rochester; Other
Eligibility: 21 Years and older · Female only
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Breast Cancer, Breast Cancer Female, Cancer of Breast
Interventions: Bupivacaine, Gabapentin, Celecoxib, Acetaminophen, Midazolam, Fentanyl; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older · Female only
Enrollment: 134 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Dystrophic Epidermolysis Bullosa
Interventions: PTW-002 10 mg/g gel, Placebo; Drug
Lead sponsor: Phoenicis Therapeutics; Industry
Eligibility: 4 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 3
States / cities: Stanford, California • Worcester, Massachusetts • Cincinnati, Ohio

Conditions: Breast Carcinoma
Interventions: Questionnaire Administration, White Button Mushroom Extract; Other · Drug
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 21 Years and older · Female only
Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: Duarte, California

Conditions: Melanoma, Advanced Melanoma, Metastatic Melanoma, Unresectable Melanoma
Interventions: CMP-001, Nivolumab; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 25
States / cities: Phoenix, Arizona • Duarte, California • Los Angeles, California + 21 more

Conditions: Acne Vulgaris
Interventions: Adapalene/Benzoyl Peroxide, Adapalene, Benzoyl Peroxide, Topical Gel Vehicle; Drug
Lead sponsor: Galderma R&D; Industry
Eligibility: 12 Years and older
Enrollment: 1,670 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 33
States / cities: Huntsville, Alabama • Little Rock, Arkansas • Fresno, California + 30 more

Conditions: Foot Ulcer, Diabetic, Diabetes Complications
Interventions: MRE0094, Vehicle gel; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 19
States / cities: Phoenix, Arizona • Tucson, Arizona • Fresno, California + 16 more

Conditions: Breast Cancer
Interventions: Questionnaires of Patient understanding of Pathologist input; Other
Lead sponsor: Dartmouth-Hitchcock Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Lebanon, New Hampshire

Conditions: Discoid Lupus Erythematosus
Interventions: CC-10004; Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 65 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: New York, New York

Conditions: Skin Cancer
Interventions: Optical Spectroscopy; Device
Lead sponsor: University of California, Irvine; Other
Eligibility: 18 Years and older
Enrollment: 37 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2013
U.S. locations: 2
States / cities: Irvine, California • Orange, California

Conditions: Atopic Dermatitis
Interventions: Not listed
Lead sponsor: Boston Children's Hospital; Other
Eligibility: 6 Years to 65 Years
Enrollment: 111 participants
Timeline: 2020 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Malignant Melanoma, Melanoma, Metastatic Melanoma, Solid Tumors
Interventions: PF-08046031; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 7
States / cities: Los Angeles, California • San Francisco, California • Santa Monica, California + 1 more

Conditions: Diabetic Foot Ulcers
Interventions: MEBO Wound Ointment (MEBO), Standard of Care; Drug · Other
Lead sponsor: Skingenix, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 9
States / cities: Phoenix, Arizona • Castro Valley, California • Encinitas, California + 6 more

Conditions: Skin Laxity
Interventions: Ulthera® System, Sculptra®, Sculptra® treatment followed by Ultherapy™ treatment; Device · Drug · Other
Lead sponsor: Ulthera, Inc; Industry
Eligibility: 35 Years to 60 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Dallas, Texas

Search by objective public record fields.

Breast-Conserving Surgery and Radiation Therapy in Patients With Multiple Ipsilateral Breast Cancer

A Novel Regimen for Treatment and Prevention of Post-Inflammatory Hyperpigmentation in Skin of Color

Food for Thought - A Nutrition Intervention for Women Undergoing Active Treatment for Triple Negative Breast Cancer

The Lipid Profile of the Skin Surface in Acne

Food-Specific and Component IgE Threshold Levels That Predict Food Allergy in People With Elevated Total Serum IgE Levels and Atopic Dermatitis

Photodynamic Therapy Clinical Trial For Cutaneous AIDS-Related Kaposi's Sarcoma Study Summary.

A Study of Safety, Tolerability, and Efficacy of AFN-12520000 in the Treatment of Acute Bacterial Skin and Skin Structure Infections Due to Staphylococci

Advanced Diffusion Tensor MRI for Breast Cancer

Investigation of Three Approaches to Address Fear of Recurrence Among Breast Cancer Survivors

Omega-3 Fatty Acid in Treating Pain in Patients With Breast or Ovarian Cancer Receiving Paclitaxel

Curcumin for the Prevention of Radiation-induced Dermatitis in Breast Cancer Patients

PECS Block vs. Multimodal Analgesia for Prevention of Persistent Postoperative Pain in Breast Surgery

Study of PTW-002 in Patients With Dominant or Recessive Dystrophic Epidermolysis Bullosa Due to Mutation(s) in Exon 73 of the COL7A1 Gene

Effects of White Button Mushroom on Inflammation in Obese Postmenopausal Women at High Risk of Breast Cancer

CMP-001 in Combination With Nivolumab in Subjects With Advanced Melanoma

A Study to Demonstrate the Efficacy and Safety of Adapalene/Benzoyl Peroxide Topical Gel in Subjects With Acne Vulgaris

Safety and Efficacy Study of MRE0094 to Treat Large, Single or Multiple, Chronic, Neuropathic, Diabetic Foot Ulcers

24GUT540 : Meeting of Breast Cancer Patients and Pathologists

Safety Study of Clinical and Immune Effects of Phosphodiesterase 4 (PDE-4) Inhibitor in Cutaneous Lupus Patients

A Pilot Study to Evaluate Optical Spectroscopy of Pigmented Skin Lesions

Mechanisms of Increased Disease Severity in AD Patients With the IL-4Ra R576 Polymorphism

A Study to Learn About the Study Medicine Called PF-08046031 in Advanced Melanoma and Other Solid Tumors

A Clinical Study of the Safety and Efficacy of MEBO Wound Ointment in Subjects With Diabetic Foot Ulcers

Ultherapy™ Treatment Following Sculptra® Treatment